AbbVie’s immunology heirs Skyrizi and Rinvoq are proving booming growth to make up for once-king Humira’s continuous sales slide. With an upcoming FDA decision for Skyrizi and a new edge over a major ...
It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. Humira heir Skyrizi has been slowly creeping up on ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, ...
On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an ...
Everyday Health on MSN
Don’t Give Up on Finding the Right Psoriasis Treatment
Discover tips on navigating psoriasis treatments with resilience. Learn from a personal journey through six biologics, emphasizing hope and perseverance.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Sales of Skyrizi and Rinvoq ...
April 26 (Reuters) - AbbVie (ABBV.N), opens new tab expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as ...
People with psoriatic arthritis (PsA) often take medicines to help manage their condition and improve their symptoms. Some of these medicines work directly on the body’s immune system and help to ...
Please provide your email address to receive an email when new articles are posted on . Maintenance subcutaneous risankizumab may induce remission in patients with ulcerative colitis who failed IV ...
Skyrizi was the top Rx and over-the-counter (OTC) pharma brand advertising on TV in 2024, according to data released by iSpot.tv on Thursday afternoon. AbbVie’s psoriasis, ulcerative colitis, Crohn’s ...
AbbVie Q4 adjusted EPS of $2.16 beat estimates, with strong sales of Skyrizi (+57.9%) and Rinvoq (+47.1%) boosting revenue growth. AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback